Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Zimmer Biomet Holdings is conducting a study titled ‘Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Comprehensive® Primary Revision Stems.’ The study aims to gather long-term data on the safety, performance, and clinical benefits of Comprehensive Primary Revision Stems used in shoulder arthroplasty over periods of 1, 3, 5, 7, and 10 years. This research is significant as it seeks to validate the effectiveness and safety of these medical devices in treating various shoulder conditions.
Intervention/Treatment: The intervention being tested is the Comprehensive Primary Revision Stems, a type of medical device used in shoulder arthroplasty. The primary purpose of these stems is to improve outcomes for patients suffering from shoulder pain, injuries, fractures, diseases, and arthritis.
Study Design: This is an observational study involving a consecutive cohort of 59 cases, both male and female, who have been implanted with the Comprehensive Primary Revision Stem. The study does not involve any allocation or masking, focusing instead on observing outcomes over time.
Study Timeline: The study began on January 17, 2025, with the latest update submitted on July 8, 2025. These dates are crucial as they indicate the study’s current status and progress, which is essential for stakeholders tracking its development.
Market Implications: The ongoing study could potentially impact Zimmer Biomet’s stock performance positively by reinforcing investor confidence in the company’s product offerings. As the study aims to demonstrate the long-term benefits of their devices, successful outcomes could enhance Zimmer Biomet’s competitive position in the medical device industry, particularly in the orthopedic sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.